Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 5/20 | 0.57 |
| ▸ | FDPS | P14324 | 12/20 | 0.57 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7161109 | 0.90 | GGPS1 (0.48) | GGPS1FDPSBTN3A1PDE3AACHE | |
| SCHEMBL7164214 | 0.84 | GGPS1 (0.40) | GGPS1FDPSBTN3A1PDE3AACHE | |
| SCHEMBL12257793 | 0.79 | FDPS (0.62) | GGPS1FDPSBTN3A1PDE3A | |
| SCHEMBL7161084 | 0.76 | FDPS (0.62) | GGPS1FDPSBTN3A1PDE3A | |
| SCHEMBL10882216 | 0.76 | FDPS (0.63) | GGPS1FDPSBTN3A1PDE3A | |
| SCHEMBL3846830 | 0.74 | FDPS (1.00) | GGPS1FDPSBTN3A1PDE3A | |
| SCHEMBL7165885 | 0.73 | ACHE (0.41) | ACHE | |
| SCHEMBL13431339 | 0.73 | GGPS1 (1.00) | GGPS1FDPSBTN3A1PDE3A | |
| SCHEMBL9781053 | 0.73 | ACHE (0.46) | ACHE | |
| SCHEMBL12257812 | 0.73 | GGPS1 (0.76) | GGPS1FDPSBTN3A1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548042-B2 | Such as tetraethyl-N-(m-trimethylsilylphenylethyl)amino-methylenebisphosphonate for palliative and curative treatment of bone disorders and breast cancer | ARSTAD ERIK (NO) | 2003-04-15 | — | — | US | disclosed |
| US-20020042539-A1 | Bis-phosphonate compounds | ARSTAD ERIK (NO) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042539-A1 | Bis-phosphonate compounds | PHOSPHO1, PTMS, PTEN | GGPS1 119/4885FDPS 599/4885BTN3A1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.